Intrathecal interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibits an anti-allodynic action in a rat model of neuropathic pain
S. Sweitzer et al., Intrathecal interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibits an anti-allodynic action in a rat model of neuropathic pain, NEUROSCIENC, 103(2), 2001, pp. 529-539
The expression of interleukin-1 beta and tumor necrosis factor has previous
ly been shown to be up-regulated in the spinal cord of several rat mononeur
opathy models. This present study was undertaken to determine whether block
ing the action of central interleukin-1 beta and tumor necrosis factor atte
nuates mechanical allodynia in a gender-specific manner in a rodent L5 spin
al nerve transection model of neuropathic pain, and whether this inhibition
occurs via down-regulation of the central cytokine cascade or blockade of
glial activation. Interleukin-1 receptor antagonist or soluble tumor necros
is factor receptor was administered intrathecally via lumbar puncture to ma
le Holtzman rats in a preventative pain strategy, in which therapy was init
iated 1 h prior to surgery. Administration of soluble tumor necrosis factor
receptor attenuated mechanical allodynia, while interleukin-1 receptor ant
agonist alone was unable to decrease allodynia. Interleukin-1 receptor anta
gonist in combination with soluble tumor necrosis factor receptor, administ
ered to both male and female rats in a preventative pain strategy, signific
antly reduced mechanical allodynia in a dose-dependent manner (P < 0.01). T
he magnitude of attenuation in allodynia was similar in both males and fema
les. Immunohistochemistry on LS spinal cord revealed similar astrocytic and
microglial activation regardless of treatment. At days 3 and 7 post-transe
ction, animals receiving daily interleukin-1 receptor antagonist in combina
tion with soluble tumor necrosis factor receptor exhibited significantly le
ss interleukin-6, but not interleukin-1<beta>, in the L5 spinal cord compar
ed to vehicle-treated animals. In an existing pain paradigm, in which treat
ment was initiated on day 7 post-transection, interleukin-1 receptor antago
nist in combination with soluble tumor necrosis factor receptor attenuated
mechanical allodynia (P < 0.05) in male rats.
These findings further support a role for central interleukin-1<beta> and t
umor necrosis factor in the development and maintenance of neuropathic pain
through induction of a proinflammatory cytokine cascade. (C) 2001 IBRO. Pu
blished by Elsevier Science Ltd. All rights reserved.